Full Year 2023 Investor Presentation
41
Investor presentation
Full year 2023
The total branded diabetes market has a global value of DKK
~420 billion annually
DKK
billion
Global diabetes market
DKK
The USA
billion
500
+21%
+17%
2022/2023 2021/2022 Growth at CER
300
215
419
+41%
200
175
129
400
-25%
+39%
363
90
-18%
100
31 40
13 16
42 30
0
300
Total
Insulin
GLP-1
DPP-4i
SGLT-2i
+43%
DKK
billion
Outside the USA
200
185
300
+13%
-12%
130
+40%
109
95
-19%
94
200
204 188
100
-4%
69
+45%
56
-19%
+41%
44
100
64 69
56
40
31 40
53
39
0
Total
Insulin
GLP-1
DPP-4i
SGLT-2i
0
Total
Insulin
GLP-1
Source: Company announcements as of Q3 2023; 2022/2023 data based on Q4 2022 to Q3 2023 and 2021/2022 data based on Q4 2021 to Q3 2022
Note: The segment value is based on reported figures, whilst the market growth is under constant exchange rate (CER). For Novo Nordisk the diabetes growth includes Insulin and GLP-1, excluding 'other Diabetes care'.
DPP-4i
SGLT-2i
Novo NordiskⓇView entire presentation